Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society
G. Tedeschi(Italian Medicines Agency), Angelo Ghezzi, Domenico Caputo(Don Carlo Gnocchi Foundation), Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Antonio Bertolotto(Neuroscience Institute), Leandro Provinciali(Ospedali Riuniti di Ancona), E. Montanari(University of Milan), Maria Giovanna Marrosu(University of Cagliari), María Trojano(University of Bari Aldo Moro), Giovanni Savettieri(University of Palermo), Alessandra Lugaresi(Istituto delle Scienze Neurologiche di Bologna), L. M. E. Grimaldi(University of Cagliari), Ruggero Capra(Presidio Ospedaliero), Maria Pia Amato(University of Florence), Stefano Sotgiu(Centro Studi GISED), Paolo Gallo(University of Padua), Luca Durelli(University of Turin), Enrico Millefiorini(Policlinico Umberto I), Carlo Pozzilli(Sapienza University of Rome), Gianluigi Mancardi(Istituti Clinici Scientifici Maugeri), Vincenzo Brescia Morra(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), M. R. Tola(Vita-Salute San Raffaele University), P. Bellantonio(Istituto Neurologico Mediterraneo), Salvatore Cottone, Diego Centonze(University of Rome Tor Vergata), Giancarlo Comi(University of Milan)
Cited by 19
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|959